Introduction of Prescription Oral Antivirals for COVID-19 to the CommercialMarket

Relevant to: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

The Centers for Medicare & Medicaid Services (CMS) is issuing this guidance to expand upon the guidance provided in the November 4, 2022 memorandum, “Part D Coverage of Oral Antivirals for COVID-19,” in the context of the transition of oral antivirals for COVID-19 to the commercial market.

See the full guidance for more information.